Predictive biomarkers of overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/− bevacizumab: Results from CALGB 90206 (Alliance)
- Resource Type
- Authors
- Nixon, Andrew B.; Halabi, Susan; Liu, Yingmiao; Starr, Mark D.; Brady, John C.; Shterev, Ivo; Luo, Bin; Hurwitz, Herbert I.; Febbo, Phillip G.; Rini, Brian I.; Beltran, Himisha; Small, Eric J.; Morris, Michael J.; George, Daniel J.
- Source
- Clin Cancer Res
- Subject
- Article
- Language
- English
PURPOSE: CALGB 90206 was a phase III trial of 732 mRCC patients comparing bevacizumab plus interferon alpha (BEV+IFN) versus interferon alpha alone (IFN). No difference in overall survival (OS) was observed. Baseline samples were analyzed to identify predictive biomarkers for survival benefit. EXPERIMENTAL DESIGN: A total of 32 biomarkers were assessed in 498 consenting patients randomly assigned into training (n=279) and testing (n=219) sets. The proportional hazards model was used to test for treatment arm and biomarker interactions of OS. The estimated coefficients from the training set were used to compute a risk score for each patient and to classify patients by risk in the testing set. The resulting model was assessed for predictive accuracy using the time-dependent area under the receiver operating characteristic curve (tAUROC). RESULTS: A statistically significant 3-way interaction between IL-6, HGF, and bevacizumab treatment was observed in the training set and confirmed in the testing set (p